ClinicalTrials.gg
CompletedNCT00590213COMARTUpdated Jan 25, 2008

Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX

A Phase 4 interventional study of Casodex 150mg and Radiotherapy in Prostate Cancer, sponsored by AstraZeneca. Completed at 9 sites in Turkey. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-01-25.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing bicalutamide in Prostatic Neoplasms — 5 open to participants now, 9 under way, 3 of them phase 3. bicalutamide · Prostatic Neoplasms.

Planned enrollment
18th of 54
125 · median 53
Started
2003
with 2 others
Phase 4
5 of 55
none open now
Registered
23rd of 55
by date
Lead sponsor
8 of 55
AstraZeneca

Among the 55 studies testing bicalutamide in Prostatic Neoplasms, this one is the 18th largest by planned enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2003, is one of 5 in phase 4, and was the 23rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 55 studies testing bicalutamide in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About bicalutamide

bicalutamide: first FDA approval 1995 (CASODEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing bicalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The primary objective of this trial is to examine the value of prophylactic versus therapeutic breast radiotherapy in Casodex monotherapy induced gynaecomastia and/or breast pain. Patients will receive either prophylactic radiotherapy to the breast at a dose of 12Gy (as two fractions of 6 Gy in consecutives days), or will not receive any radiotherapy prior to commencing CASODEX 150mg monotherapy.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Casodex
  • Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males patients aged 18 years or over on entry into the trial
  • Patients who have non- cancer that is confirmed by histology or cytology. This primary treatment should have been completed in the last 8 weeks
  • The stage should be T1b/T1c/T2/T3/T4 any N category
  • Paitents must have given written, fully to participate in the trial prior to any trial specific assessments being made
  • Be able and prepared to comply with trial procedures and restrictions
  • Have a greater than 2 years

Exclusion criteria

Exclusion Criteria:

  • Any known sensitivity to radiation therapy or any conditions which in the investigator's opinion may lead to radiation sensitivity
  • Patients with any concurrent (except for basal cell or TO-2 NO MO squamous cell carcinoma of the skin). History of previous malignancy or treatment for any cancer in the past 5 years
  • Previous history of mastectomy including a Webster operation or radiation therapy to the chest area
  • Any previous treatment with surgical or medical castration, anti-androgens, monotherapy or oestrogen therapy at any time
  • Any evidence of pre-existing gynaecomastia or breast pain
  • Patients with history or presence of testicular abnormalities (as CASODEX can potentially aggravate testicular tumours)
  • Patients with any concurrent disease or condition that in the opinion of the treating physician, would constitute a hazard for participation in this study or may interfere with the patient's ability to comply with the scheduled visits and assessments. This includes patients whose physical build would prevent reasonable assessment of gynaecomastia
  • Liver disease ( greater than 2.0mg/dL; /ALT greater than 2 times the upper limit or normal)
  • Patients taking the following drugs; terfenadine, cisapride, astemizole, cyclosporin, and warfarin are excluded from the trial due to the possibility of drug interaction
  • Patients with a known history of alcohol abuse
  • Concurrent treatment with any druges known to have high potential for causing gynaecomastia or breast pain, eg.Spironolactone, therapy, cimetidine and neuroleptic agents.
  • Treatment with a new chemical entity within the previous 4 months or current participation in another clinical trial involving an product
  • Patients considered by the investigator to be at risk of transmitting any infection through the body or other body fluids, including acquired immue dificiency syndrome (AIDS) other sexually transmitted diseases or hepatitis
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
125 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. To examine the value of prophylactic versus therapeutic breast radiotherapy in Casodex monotherapy induced gynaecomastia and/or breast pain

Secondary outcomes

  1. To examine the tolerability of radiotherapy to male breast

  2. To examine the tolerability of Casodex 150mg in localized and locally advanced prostate cancer patients

  3. To examine the efficacy of Casodex 150mg in prostate cancer patients

07

Study locations

9 sites
  • Research Site
    Adana, Turkey
  • Research Site
    Ankara, Turkey
  • Research Site
    Diyarbak?r, Turkey
  • Research Site
    Edirne, Turkey
  • Research Site
    Eskisehir, Turkey
  • Research Site
    Istanbul, Turkey
  • Research Site
    Izmir, Turkey
  • Research Site
    Manisa, Turkey
  • Research Site
    Samsun, Turkey
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 25, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00590213
Lead sponsor
AstraZeneca
First posted
Jan 10, 2008
Start date
Jun 2003
Last update
Jan 25, 2008

Study contacts

Haluk Ozen, Prof
principal investigator · Hacettepe Univ. Med. Fac

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bicalutamide

Start the discussion